Showing results (1361-1370 of 1,390) with videos related to
Sort By:
Pageof 139
Journal of Medicinal Chemistry|September 10, 1999
Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimizationY M Choi-Sledeski, D G McGarry, D M Green, et al.JAMA Cardiology|March 5, 2025
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance SubstudyJohn W Ostrominski, Brian L Claggett, Michael Jerosch-Herold, et al.Frontiers in Immunology|October 29, 2024
Surviving septic patients endotyped with a functional assay demonstrate active immune responsesAdam D Price, Ellen R Becker, Evan L Barrios, et al.Circulation. Heart Failure|May 9, 2025
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical TrialConstantin-Cristian Topriceanu, Christoffer Rasmus Vissing, Anna Axelsson Raja, et al.Nature|July 19, 2023
Organization of the human intestine at single-cell resolutionJohn W Hickey, Winston R Becker, Stephanie A Nevins, et al.Nature Cancer|October 31, 2024
Multiomic analysis of familial adenomatous polyposis reveals molecular pathways associated with early tumorigenesisEdward D Esplin, Casey Hanson, Si Wu, et al.Science Advances|October 9, 2020
Hemispherical differences in the shape and topography of asteroid (101955) BennuM G Daly, O S Barnouin, J A Seabrook, et al.Nature Medicine|September 24, 2021
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialCarolyn Y Ho, Sharlene M Day, Anna Axelsson, et al.The New England Journal of Medicine|November 3, 2016
Fulminant Myocarditis with Combination Immune Checkpoint BlockadeDouglas B Johnson, Justin M Balko, Margaret L Compton, et al.JAMA Cardiology|September 6, 2023
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical TrialChristoffer Rasmus Vissing, Anna Axelsson Raja, Sharlene M Day, et al.Pageof 139